Article Text

Download PDFPDF
Prognostic Factors for Locally Advanced Cervical Cancer Treated With Neoadjuvant Intravenous and Transuterine Arterial Chemotherapy Followed by Radical Hysterectomy
  1. Hiroshi Tsubamoto, MD, PhD*,
  2. Satoshi Yamamoto, MD, PhD,
  3. Riichiro Kanazawa, MD, PhD*,
  4. Riya Sakane, MD*,
  5. Okuto Honda, MD*,
  6. Kaoru Kobayashi, MD,
  7. Hiroaki Shibahara, MD, PhD* and
  8. Shozo Hirota, MD, PhD
  1. *Departments of Obstetrics and Gynecology, and
  2. Departments of Radiology, Hyogo College of Medicine, Hyogo, Japan.
  1. Address correspondence and reprint requests to Hiroshi Tsubamoto, MD, PhD, Department of Obstetrics and Gynecology, Hyogo College of Medicine, Mukogawa 1-1, Nishinomiya, Hyogo 663-8501, Japan. E-mail: tsuba@hyo-med.ac.jp.

Abstract

Objective The aim of this study was to identify prognostic factors associated with neoadjuvant transuterine arterial chemotherapy (TUAC) followed by type III radical hysterectomy.

Methods The medical histories of patients with stage IB2 to IIB cervical cancer who received neoadjuvant TUAC between 1996 and 2009 at our institution were retrospectively reviewed.

Results Seventy-three patients received TUAC using cisplatin combined with intravenous nedaplatin, irinotecan, paclitaxel, or etoposide administration. Forty-seven patients (64%) had squamous cell carcinoma. The radiological response rate was 96% (95% confidence interval, 91%–100%). Radical hysterectomy was completed for 95% of enrolled patients. Examination of the resected cervical specimens showed that tumor cells were absent in 19 cases and stromal invasion was less than 3 mm in 7 cases. Among these 26 patients, 23 (32%) had pathologically negative pelvic lymph nodes and no recurrence during the follow-up period. The 5-year relapse-free survival and overall survival rates were 69% and 74%, respectively. Among 23 patients with recurrence or progressive disease, the median survival time after recurrence or progression was 12 months. In multivariate analysis, a tumor size of more than 60 mm and pathological positive lymph nodes were negative prognostic factors for overall survival.

Conclusions Tumor size, pathological response, and lymph node metastases were prognostic factors for cervical cancer. The high pathological response rate associated with TUAC makes it a promising treatment for bulky cervical cancer.

  • Neoadjuvant chemotherapy
  • Transuterine arterial chemotherapy
  • Adenocarcinoma
  • Cervical cancer
  • Pathological response

Statistics from Altmetric.com

Footnotes

  • The authors declare no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.